<DOC>
	<DOCNO>NCT00616460</DOCNO>
	<brief_summary>To determine safety/efficacy Bivallirudin Vs unfractionated heparin ( UFH ) top dual antiplatelet therapy patient high tendency bleed urgent elective PCI .</brief_summary>
	<brief_title>ACRIPAB- Trial : Anti Coagulation Regimen In High Risk PAtients Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>Inclusion criterion ( follow ) : â‰¥75 year Creatinin clearance rate &lt; 60 ml per minute Anemia ( Hb 911 mg % ) Hypertension : BP &gt; 180/95 mmHg less 210/110 Hg Diabetic Pts Steroid treat Pts Recent ( within 6 week ) non major surgery Pts hematological disorder associate tendency bleed like Thrombocytopenia ( platelet 50000150000 ) include TTP ; Exclusion criterion : Age &lt; 18 year Acute STEMI ( Primary PCI ) * Rescue angioplasty &lt; 12h lytic therapy* Active bleed S.C LMWH &lt; 8 hour UFH &lt; 4 hour PCI Using IIb /IIIa upstream therapy PCI PCI involve obligatory IIb /IIIa therapy : ( thrombotic complication , occlusive dissection ) INR &gt; 1.5 day cathetrization Bolus 600mg Clopidogrel PCI Current pregnancy woman reproductive age without contraceptive Hypersensitivity heparin bivalirudin component * ( possible use IIB/IIIA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>